NIH Reform Act
- Bill Number
- S. 664
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-20: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-05T22:48:26Z
AI-Generated Summary
Purpose of the Legislation
The NIH Reform Act (S. 664) aims to reorganize the National Institutes of Health (NIH) by dividing the existing National Institute of Allergy and Infectious Diseases (NIAID) into three separate, specialized research institutes. This restructuring seeks to create more focused efforts on specific health areas: allergic diseases, infectious diseases (including tropical diseases), and immunologic diseases and disorders.
Key Provisions
- Creation of New Institutes:
- Establishes the National Institute of Allergic Diseases, focused on research, training, and information on allergic diseases and disorders.
- Establishes the National Institute of Infectious Diseases, dedicated to infectious diseases, including tropical diseases.
- Establishes the National Institute of Immunologic Diseases, centered on immunologic diseases and disorders.
- Director Appointments:
- Directors for each new institute are appointed by the President with Senate confirmation (advice and consent).
- Terms are 5 years, with the option for one reappointment.
- During transition, the NIH Director oversees the new institutes until directors are appointed.
- Transfer of Responsibilities:
- Existing NIAID duties and authorities related to each focus area are reassigned to the corresponding new institute.
- The NIAID Director position is terminated upon enactment.
- Administrative Updates:
- Amends the Public Health Service Act to update institute listings, headings, and references.
- Ensures orderly transition by requiring the NIH Director to handle any necessary shifts in operations, staff, and resources.
- References in Law: All prior legal references to NIAID are redirected to the appropriate new institute based on the topic.
Significant Changes to Existing Law
- Structural Reorganization: Replaces the single NIAID (one of 27 NIH institutes) with three new ones, increasing the total number of NIH institutes to 29. This splits combined research on allergies, immunology, and infections into distinct entities.
- Appointment Process: Introduces Senate confirmation for the new directors, which was not explicitly required for the prior NIAID Director in the same way. Previously integrated duties under NIAID are now separated and codified in new subparts of the Public Health Service Act.
- Purpose Redefinition: Narrows NIAID's former broad mandate (covering allergies, immunology, and infections) into specialized purposes for each new institute, with specific sections transferred and redesignated.
Potential Impacts
- On Government Agencies: The NIH will experience internal restructuring, potentially leading to more targeted allocation of research funding and resources. This could streamline operations but may require short-term adjustments in budgeting, staffing, and coordination among the new institutes.
- On Citizens: Patients and communities affected by allergic, infectious, or immunologic conditions may benefit from more specialized research and health programs, potentially accelerating advancements in treatments and prevention. However, the transition could temporarily disrupt ongoing projects.
- On International Relations: Minimal direct impact, though enhanced focus on infectious and tropical diseases could strengthen U.S. contributions to global health efforts, such as pandemic preparedness or collaborations on diseases like malaria.
Main Stakeholders Affected
- NIH and Federal Health Agencies: Directly involved in implementation, including the NIH Director and staff managing the transition.
- Researchers and Medical Professionals: Scientists, clinicians, and trainees working on allergies, infections, or immunology, who may see shifts in funding priorities and institutional support.
- Patients and Advocacy Groups: Individuals and organizations focused on allergic reactions (e.g., asthma), infectious diseases (e.g., HIV, COVID-19), or immunologic disorders (e.g., autoimmune diseases like lupus).
- Congress: Senators and committees (e.g., Health, Education, Labor, and Pensions) overseeing confirmations and funding.
- Pharmaceutical and Biotech Industries: Companies involved in related drug development, potentially influenced by more focused NIH research directions.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: The bill amends the Public Health Service Act (a foundational law for U.S. public health) without altering core funding mechanisms, ensuring continuity in NIH operations. It mandates an "orderly transition" to avoid legal disruptions in ongoing research contracts or grants.
- Constitutional Implications: Aligns with Congress's authority under Article I to establish and organize federal agencies. The Senate confirmation requirement reinforces the constitutional "advice and consent" role in executive appointments.
- Political Implications: As an introduced bill (not yet law), it reflects priorities of sponsors (Senators Paul and Tuberville) for NIH reform. If enacted, it could spark debates on agency efficiency versus potential fragmentation, but the legislation itself focuses solely on structural changes without addressing broader policy controversies.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-02-20: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-02-20: Introduced in Senate
Bill Versions
- NIH Reform Act — issued 2025-02-20 — PDF (8 pages)